Report Detail

Request for Sample of this report

Other Global Acute Myeloid Leukemia (AML) Biomarker Testing Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4507836
    • |
  • 04 February, 2023
    • |
  • Global
    • |
  • 88 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global Acute Myeloid Leukemia (AML) Biomarker Testing market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Acute Myeloid Leukemia (AML) Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts, in consumption value ($ Million), 2018-2029
Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Acute Myeloid Leukemia (AML) Biomarker Testing market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acute Myeloid Leukemia (AML) Biomarker Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acute Myeloid Leukemia (AML) Biomarker Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc. and Sysmex Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Acute Myeloid Leukemia (AML) Biomarker Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Market segment by Application
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
Market segment by players, this report covers
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Acute Myeloid Leukemia (AML) Biomarker Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Acute Myeloid Leukemia (AML) Biomarker Testing, with revenue, gross margin and global market share of Acute Myeloid Leukemia (AML) Biomarker Testing from 2018 to 2023.
Chapter 3, the Acute Myeloid Leukemia (AML) Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Acute Myeloid Leukemia (AML) Biomarker Testing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukemia (AML) Biomarker Testing.
Chapter 13, to describe Acute Myeloid Leukemia (AML) Biomarker Testing research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Biomarker Testing
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Acute Myeloid Leukemia (AML) Biomarker Testing by Type
    • 1.3.1 Overview: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type in 2022
    • 1.3.3 Genetic Acute Myeloid Leukemia (AML) Biomarker
    • 1.3.4 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
    • 1.3.5 Proteomic Acute Myeloid Leukemia (AML) Biomarker
  • 1.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market by Application
    • 1.4.1 Overview: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals
    • 1.4.3 Cancer diagnostic Centers
    • 1.4.4 Research Institutes
    • 1.4.5 Others
  • 1.5 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size & Forecast
  • 1.6 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast by Region
    • 1.6.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region, (2018-2029)
    • 1.6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)
    • 1.6.6 South America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Abbott Laboratories
    • 2.1.1 Abbott Laboratories Details
    • 2.1.2 Abbott Laboratories Major Business
    • 2.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.1.4 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Abbott Laboratories Recent Developments and Future Plans
  • 2.2 Novartis AG
    • 2.2.1 Novartis AG Details
    • 2.2.2 Novartis AG Major Business
    • 2.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.2.4 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Novartis AG Recent Developments and Future Plans
  • 2.3 Thermo Fisher Scientific
    • 2.3.1 Thermo Fisher Scientific Details
    • 2.3.2 Thermo Fisher Scientific Major Business
    • 2.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.3.4 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.4 Cancer Genetics Inc.
    • 2.4.1 Cancer Genetics Inc. Details
    • 2.4.2 Cancer Genetics Inc. Major Business
    • 2.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.4.4 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Cancer Genetics Inc. Recent Developments and Future Plans
  • 2.5 Sysmex Corporation
    • 2.5.1 Sysmex Corporation Details
    • 2.5.2 Sysmex Corporation Major Business
    • 2.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.5.4 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Sysmex Corporation Recent Developments and Future Plans
  • 2.6 Epigenomics AG
    • 2.6.1 Epigenomics AG Details
    • 2.6.2 Epigenomics AG Major Business
    • 2.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.6.4 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Epigenomics AG Recent Developments and Future Plans
  • 2.7 BioMerieux SA
    • 2.7.1 BioMerieux SA Details
    • 2.7.2 BioMerieux SA Major Business
    • 2.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.7.4 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 BioMerieux SA Recent Developments and Future Plans
  • 2.8 Skyline DX B.V.
    • 2.8.1 Skyline DX B.V. Details
    • 2.8.2 Skyline DX B.V. Major Business
    • 2.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions
    • 2.8.4 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Skyline DX B.V. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Acute Myeloid Leukemia (AML) Biomarker Testing by Company Revenue
    • 3.2.2 Top 3 Acute Myeloid Leukemia (AML) Biomarker Testing Players Market Share in 2022
    • 3.2.3 Top 6 Acute Myeloid Leukemia (AML) Biomarker Testing Players Market Share in 2022
  • 3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Overall Company Footprint Analysis
    • 3.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Region Footprint
    • 3.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Type Footprint
    • 3.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)
  • 6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)
  • 6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country
    • 6.3.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)
    • 6.3.2 United States Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)
  • 7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)
  • 7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country
    • 7.3.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 7.3.3 France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region
    • 8.3.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2018-2029)
    • 8.3.2 China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 8.3.5 India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)
  • 9.2 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)
  • 9.3 South America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country
    • 9.3.1 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country
    • 10.3.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
  • 11.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
  • 11.3 Acute Myeloid Leukemia (AML) Biomarker Testing Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Chain
  • 12.2 Acute Myeloid Leukemia (AML) Biomarker Testing Upstream Analysis
  • 12.3 Acute Myeloid Leukemia (AML) Biomarker Testing Midstream Analysis
  • 12.4 Acute Myeloid Leukemia (AML) Biomarker Testing Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Acute Myeloid Leukemia (AML) Biomarker Testing. Industry analysis & Market Report on Acute Myeloid Leukemia (AML) Biomarker Testing is a syndicated market report, published as Global Acute Myeloid Leukemia (AML) Biomarker Testing Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Acute Myeloid Leukemia (AML) Biomarker Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo